Session Overview
In this session, Dr. Brandon Turner explores advanced strategies for fully leveraging the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs to support research & development. The discussion focuses on funding mechanisms beyond the traditional Phase I and Phase II pathways, including supplemental programs, institute-specific opportunities, and commercialization-focused extensions that can significantly expand a company’s non-dilutive funding strategy.
Session Recap
- While Phase I and Phase II submissions make up the majority of applications, they represent only ~55% of total NIH SBIR funding.
- Nearly 45% of funding flows through additional mechanisms, including:
-
- Direct-to-Phase II
-
- Fast Track
-
- Phase IIB
-
- Commercialization Readiness Pilot (CRP)
-
- Administrative Supplements
-
- Targeted RFAs
-
- Contracts and Cooperative Agreements
- Companies that look beyond standard omnibus submissions can significantly increase their funding opportunities.
- Funding success is highly dependent on selecting the right NIH Institute or Center (IC).
- Each IC differs in:
-
- Funding priorities
-
- Budget flexibility and waiver policies
-
- Participation in Phase IIB, CRP, and clinical trial programs
-
- Paylines or “zones of consideration”
- Key tools to guide alignment:
-
- NIH RePORTER (analyze funded projects)
-
- Matchmaker tool (compare abstract similarity)
-
- PHS Assignment Request Form (request specific IC and study section)
-
- Engaging program officers early is critical for confirming fit, budget strategy, and clinical trial eligibility.
- Direct-to-Phase II
-
- Allows companies with strong preliminary data to skip Phase I.
-
- Requires clear proof of feasibility and commercialization readiness.
- Fast Track
-
- Combines Phase I and Phase II in one submission.
-
- Eliminates funding gap between phases.
-
- Requires well-defined Phase I milestones.
- Phase IIB
-
- Extends Phase II funding for complex, capital-intensive technologies.
-
- Often supports regulatory advancement.
-
- Frequently requires third-party matching funds.
- Commercialization Readiness Pilot (CRP)
-
- Supports commercialization activities (market research, licensing, regulatory strategy).
-
- Less R&D-intensive than Phase IIB.
-
- More flexible outsourcing structure.
- Many NIH institutes allow budget waivers above standard caps when aligned with specific topic areas.
- Phase I budget may exceed $300K.
- Phase II budget may exceed $2M.
- Notices of Special Interest (NOSIs) can:
-
- Signal high-priority topics
-
- Expand allowable budgets
-
- Increase programmatic interest
-
- Applications must explicitly reference the NOSI in Field 4B.
- Technical and Business Assistance (TABA)
-
- $6,500 (Phase I)
-
- Up to $50,000 (Phase II)
-
- Supports regulatory planning, IP strategy, and market analysis
- Administrative Supplements
-
- Add new scientific aims
-
- Support diversity initiatives
-
- Expand ongoing awards
-
- Must be requested at least six months before award end
- Omnibus Solicitations
-
- Broad, investigator-initiated topics
-
- Typically more competitive
- Requests for Applications (RFAs)
-
- Targeted, topic-specific calls
-
- Often smaller applicant pools
-
- Frequently include set-aside funding
-
- May allow higher budget caps
-
- The same project cannot be submitted to both an RFA and the omnibus in the same cycle
- Grants (R43/R44/R01)
-
- High investigator independence
-
- Minimal NIH involvement
- Cooperative Agreements (U44/U01)
-
- Greater NIH scientific involvement
-
- Often used for milestone-driven programs
- Contracts
-
- NIH purchases specific services or deliverables
-
- Highly defined scope
-
- Often faster award timelines
-
- Found via SAM.gov
- Do not treat SBIR Phase I and II as the only pathway.
- Nearly half of NIH SBIR funding exists beyond the traditional phases.
- Strategic IC alignment can significantly influence success.
- Leverage waivers, supplements, and advanced mechanisms to extend runway.
- Engage program officers early and often.
- Use NIH data tools to guide submission strategy.
- A diversified SBIR/STTR approach strengthens long-term commercialization and reduces funding gaps.
